A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Belani, Chandra Prakash
Yamamoto, Nobuyuki
Bondarenko, Igor
Orlov, Sergey V.
Tang, Jie
Niethammer, Andreas G.
Ingrosso, Antonella
Kim, Sinil
Scagliotti, Giorgio
机构：
[1] Penn State Hershey Canc Inst, Hershey, PA USA
[2] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
[3] Dnipropetrovsk State Med Acad, Dnepropetrovsk, Ukraine
[4] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Pfizer Italia Srl, Milan, Italy
[8] Univ Torino, Orbassano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [22] A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study
    Molina, J. R.
    Dy, G. K.
    Foster, N. R.
    Ziegler, K. L. Allen
    Adjei, A.
    Rowland, K. M.
    Aubry, M.
    Flynn, P. J.
    Mandrekar, S. J.
    Schild, S. E.
    Adjei, A. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] First-line chemotherapy (CT) with pemetrexed (PEM) plus cisplatin (CIS) plus bevacuzimab (BEV) followed by maintenance PEM plus BEV for advanced nonsquamous non-small cell lung cancer (NS-NSCLC): Final results of a single-arm phase II study.
    Hillerdal, Gunnar N.
    Sorensen, Jens Benn
    Hoeffken, Gert
    Favaretto, Adolfo
    Perez-Carrion, Ramon
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Bourayou, Nawel
    Santoro, Armando
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] PHASE I STUDY OF TISLELIZUMAB IN COMBINATION WITH BEVACIZUMAB AND PEMETREXED IN FIRST-LINE TREATMENT FOR ADVANCED ELDERLY NONSQUAMOUS NON-SMALL CELL LUNG CANCER: TRIAL IN PROGRESS
    Ren, Xiubao
    Liu, Liang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A737 - A737
  • [25] Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial
    Park, Cheol-Kyu
    Oh, In-Jae
    Kim, Kyu-Sik
    Choi, Yoo-Duk
    Jang, Tae-Won
    Kim, Youn-Seup
    Lee, Kwan-Ho
    Shin, Kyeong-Cheol
    Jung, Chi Young
    Yang, Sei-Hoon
    Ryu, Jeong-Seon
    Jang, Seung-Hun
    Yoo, Seung-Soo
    Yong, Suk-Joong
    Lee, Kye Young
    In, Kwang-Ho
    Lee, Min-Ki
    Kim, Young-Chul
    [J]. CLINICAL LUNG CANCER, 2017, 18 (04) : E289 - E296
  • [26] Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Kostas
    Biesma, Bonne
    Leschinger, Monika Iris
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott P.
    Nguyen, Tuan S.
    Hozak, Rebecca R.
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Schuette, Wolfgang
    [J]. LUNG CANCER, 2013, 81 (03) : 428 - 434
  • [27] Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Mengzhao
    Qin, Shukui
    Lu, You
    Zhang, Yang
    Zhu, Yunzhong
    Song, Xiangqun
    Wang, Xin
    Barraclough, Helen
    Zhang, Xiaoqing
    Chi, Haidong
    Orlando, Mauro
    [J]. LUNG CANCER, 2014, 85 (03) : 401 - 407
  • [28] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [29] A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
    Giaccone, Giuseppe
    Sanborn, Rachel
    Waqar, Saiama
    Martinez, Alex
    Ponce, Santiago
    Zhen, Huiling
    Kennealey, Gerard
    Erickson-Viitanen, Susan
    Schaefer, Eric
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S895 - S896
  • [30] Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study
    Tartarone, A
    Romano, G
    Iodice, G
    Capobianco, A
    Coccaro, M
    Bochicchio, A
    Di Leo, P
    Ardito, R
    Di Renzo, N
    [J]. TUMORI, 2005, 91 (02) : 131 - 134
12345